Cambridge VenturED is a new SEIS/EIS fund on a mission to invest in innovative companies at the early stages within the wider Cambridge entrepreneurial eco-system. The fund's ambition is to find the most talented teams with ground-breaking ideas that have the potential to disrupt the status-quo and ultimately create a paradigm shift. Cambridge VenturED provides an opportunity to invest in ideas that emerge into some of the world’s most exciting companies, gain exposure to Cambridge, and support early-stage potentially disruptive companies.
Dr. Ayla Selamoglu – Cambridge VenturED - Founding Partner
Dr. Ayla co-founded the Cambridge University Venture Capital and Private Equity society in 2016 where she served as President and Chair, and subsequently founded Cambridge VenturED. She holds a PhD in Psychiatry from the University of Cambridge, School of Clinical Medicine, and undertook several courses at the Cambridge Judge Business School. She completed a MSc in Neuropsychology jointly from Maastricht University/Kings’ College London, and a BSc in Psychology/Psychophysiology from Swinburne University, Australia. Dr. Ayla has a thorough understanding of the unmet clinical and scientific needs with over a decade of experience in healthcare. She also has experience in working with healthcare and life science based venture capital firms.
High / Adventurous. Capital at risk.
Companies such as FinTech, Robotics, MedTech, Sustainability, BioTech, AI/ML, Engineering, DeepTech, Healthcare, CleanTech and environment, AgriTech, Life Sciences, etc..
2.5x return after seven years
Not a reliable indicator of future income.
CURRENT STATUS - OPEN
Open to new investors. The fund will close on the 30th of June 2021. The minimum investment is £25,000 (subject to the Investment Manager's discretion to accept smaller amounts).
Before an Investment is made in any Investee Company, the Investee Company must do three things:
The Fund will seek to assist the investee companies to build their products and services helping them grow and increase in value for potential acquisition or listing opportunities. The expected holding period of most investments will be between the minimum three years for tax conditions and up to ten years. The recommended holding period for an investor is seven years. However, it is noted that investee companies may be held for longer periods. It is also noted that following the realisation of the qualifying shares in each investee company, the realisation proceeds will be paid to the investors. Consequently, it is possible that investors will receive distributions from the Fund over a period of time.
The investment committee will review potential investments to be made by the Fund and make recommendations to the Investment Manager regarding Investments. Cambridge Ventured Limited will nominate a number of suitably qualified persons as members of the investment committee. No member of the committee will be allowed to give a view on whether a company should be the subject of investment if that person has any shares in such company or is related to any person who is a director of such company or who has any other conflict of interest. In that way, the Investment Manager will receive independent recommendations on the merits of each prospective investee company.
Darktrace the cybersecurity company leverages AI techniques to better protect companies from advanced cyber attacks.
CMR Surgical is developing the next-generation surgical robotic system for minimal access surgery. CMR Surgical is to make minimal access surgery available to all.
GW Pharmaceuticals is a Cambridge based company that was founded more than two decades ago to harness the medical benefits
of marijuana and develop cannabis-based medicines.
|Full initial charge||£100|
|Annual management charge||0%|
* Performance fee is subject to a hurdle rate which must see £1 returned for each £1 invested before the performance bonus is payable.
|Annual Management Charge||2%|
Please check the fees section of the Information Memorandum for full details. All fees and charges are stated exclusive of VAT, which may be applicable in some cases. Any fees and charges payable by the investee companies or the underlying businesses do not directly come out of your investment. However, they will effectively reduce the returns generated by investee companies and therefore directly impact your investment.
To invest, you must be an eligible investor. To be an eligible investor, you must be qualifying as one or more of the following:
Important information for private investors – Reliance on the information provided here to engage in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Your attention is drawn to the risk section contained within the Information Memorandum. Investments are typically in unquoted shares in small companies, the value of which can be volatile and are often difficult to sell. Nothing on this website constitutes investment, tax, financial, legal, regulatory, or other advice by Sapphire Capital Partners LLP.
The value of an investment may go down as well as up, and you may not get back the full amount invested, and you may therefore lose some or all of your investment.
If you are unsure of the suitability of any investment for your circumstances, please contact your independent financial advisor or other professional advisor authorised under the Financial Services and Markets Act 2000 (FSMA) who specialises in advising on investments of this type. Tax reliefs depend on individual circumstances. There is no guarantee however that the tax reliefs (such as EIS reliefs, CGT reliefs or IHT relief) will be available on any investment made or that if it is initially available, it will not be subsequently withdrawn. Any references to tax laws or rates are based on current legislation, all of which are subject to change and are provided as a guide only. Prospective investors are advised to take their own investment and taxation advice and should consult their own professional advisors on the implications of investing.
Investments made in investee companies via funds managed by Sapphire Capital Partners LLP are not covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk
Past performance is not a guide to future returns.